The FDA has granted Breakthrough Device Designation to Breath Diagnostics Inc.'s OneBreath, a breath-based test that assesses postoperative pneumonia risk in cardiac surgery patients using a single preoperative sample.
Hims & Hers Health is now offering GRAIL’s Galleri multi-cancer blood test through its digital health platform, expanding access to screening for more than 50 cancer types, including those lacking established protocols.
Valley Diagnostics has secured exclusive global rights to develop point-of-care lateral flow tests for prostate cancer, lung cancer, and animal diseases, with product rollout planned for 2026.
BillionToOne has partnered with Epic to integrate its UNITY Complete prenatal and Northstar oncology tests into Epic’s EHR system, enabling direct ordering and results delivery for healthcare providers.
Read More
A study reports that post-treatment circulating tumor DNA levels may better predict recurrence in HER2-positive breast cancer patients than current pCR measures.
Read More
Labcorp has expanded its MRD testing portfolio with new personalized panels for breast and lung cancer and nationwide whole-genome MRD testing for stage III colon cancer, enabling earlier detection of recurrence via ctDNA analysis.
Read More
CITCCA data demonstrate more than 40% of high-risk stage I–III colorectal patients harbor molecular residual disease at clinical landmark, detectable only with ultrasensitive ctDNA testing.
Read More
The collaboration will combine New Day’s liquid biopsy technology with Daisy Genomics’ physics-based sequencing platform to advance early CRC screening.
Read More
Multi-year agreement will provide clinical workflow software and laboratory support for GlycoKnow liquid biopsy test.
Read More
New guidelines designate high-risk HPV testing as preferred screening method for women ages 30-65 and require insurance coverage for additional testing.
Read More
The biotechnology company’s integrated screening approach combines whole-genome sequencing, imaging, and multiple biomarker tests to enable early detection.
Read More
Three abstracts showcase PreciseBreast’s ability to predict recurrence risk in early-stage invasive breast cancer using digital pathology.
Read More
Despite effective prevention tools, Millennials are delaying screening. New approaches may help remove barriers to participation.
Read More
Study in biliary tract cancer finds the solution achieved 83.5% overall concordance rate with expert interpretations.
Read More
Researchers found that circulating tumor cell counts stratified patients by disease aggressiveness and were associated with differing outcomes following endocrine versus combination therapy.
Read More
A genomic test widely used in prostate cancer care can more accurately identify which men with early-stage disease face high risk of recurrence after treatment.
Read More
Better cancer testing can help patients avoid unnecessary scans and biopsies, while also lowering costs for the healthcare system.
Read More
The direct-to-consumer laboratory-developed test detects six cancer types with 97% sensitivity and specificity using microRNA biomarkers, according to the company.
Read More